Evidence map›Paper›PMID 40354234›Full record

ArticleJournal of visualized experiments : JoVE2025

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally.

Julianna Proietto, Betelhem Tatek, Camilla Folvar, Diana C Jimenez, Ilham M Alshiraihi, Mercedes Gonzalez-Juarrero, Fabio Saliu, Federica Vacca, Daniela Maria Cirillo, Nicolà Lore and 3 more

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Journal of bacteriology · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julianna Proietto *Center for Discovery and Innovation, Hackensack Meridian Health.
Betelhem Tatek *Center for Discovery and Innovation, Hackensack Meridian Health.
Camilla Folvar *Center for Discovery and Innovation, Hackensack Meridian Health.
Diana C JimenezMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University.
Ilham M AlshiraihiMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University; Department of Biological Sciences, College of Science, University of Tabuk.
Mercedes Gonzalez-JuarreroMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University.
Fabio SaliuEmerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute.
Federica VaccaEmerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute.
Daniela Maria CirilloEmerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute.
Nicolà LoreEmerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute.
Thomas DickCenter for Discovery and Innovation, Hackensack Meridian Health; Department of Medical Sciences, Hackensack Meridian School of Medicine; Department of Microbiology and Immunology, Georgetown University.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health; Department of Medical Sciences, Hackensack Meridian School of Medicine; veronique.dartois@hmh-cdi.org.
Wassihun Wedajo AragawCenter for Discovery and Innovation, Hackensack Meridian Health.

Funding

Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinolsU19AI142731 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI PERLIN, DAVID S · 2019 to 2023
$33.9M
Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung diseaseR01AI132374 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI Thomas Dick · 2018 to 2026
$7.0M
Shorter and more effective oral regimens for M. abscessus pulmonary diseaseR01AI184502 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI Thomas Dick · 2025 to 2026
$1.8M
NIAID NIH HHS R01 AI132374NIAID NIH HHS R01 AI184502NIAID NIH HHS U19 AI142731
6 · The paper itself

Abstract

Robust mouse models of chronic infection with Mycobacterium abscessus, an environmental pathogen that preferably infects the lungs, are badly needed. Year-long multidrug therapies deliver unacceptably poor cure rates in patients, around 50%, hence the need for predictive preclinical tools to develop better antibiotics. However, immunocompetent mice are generally resistant to pulmonary infection by M. abscessus. Numerous attempts to establish a sustained infection with M. abscessus in immunocompetent mice have been reported in the literature. Among these, methods relying on agar bead-embedded bacteria inoculated into C57BL/6 mice via the intratracheal route have proven most promising. The major limitation of this approach is the technical challenge associated with the preparation of agar beads of reproducible size and bacterial numbers, followed by intratracheal inoculation. Here, we first provide a detailed description of an optimized protocol that delivers M. abscessus-loaded agar beads of optimal diameter and reproducible bacterial burden. Next, we provide a detailed protocol of intratracheal inoculation, optimized to avoid losses of beads and bacteria due to adherence to surfaces of the inoculation devices and to achieve reproducible pulmonary deposition of agar-embedded M. abscessus. The objective is to ensure ease of implementation and excellent lab-to-lab reproducibility.

Indexed as

AgarBacteriological TechniquesMycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsDisease Models, AnimalMiceMice, Inbred C57BLTracheaAgar

Identifiers

PMID40354234
PMCPMC12355601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.